Author's response to reviews Title: Randomized phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments Authors:
نویسندگان
چکیده
Lucia Del Mastro ([email protected]) Alessandra Fabi ([email protected]) Mauro Mansutti ([email protected]) Michele De Laurentiis ([email protected]) Antonio Durando ([email protected]) Domenico Franco Merlo ([email protected]) Paolo Bruzzi ([email protected]) Ignazia La Torre ([email protected]) Matteo Ceccarelli ([email protected]) Gbenga Kazeem ([email protected]) Paolo Marchi ([email protected]) Davide Boy ([email protected]) Marco Venturini ([email protected]) Sabino De Placido ([email protected]) Francesco Cognetti ([email protected])
منابع مشابه
Gemcitabine-taxane experience in the treatment of metastatic breast cancer.
Management of metastatic breast cancer (MBC) is difficult and overall response rates (ORR) resulting from anthracycline and taxane-based regimens remain modest. The antimetabolite drug gemcitabine has been shown to have high activity when used as first-line treatment of MBC, particularly when incorporated into combined therapy regimens. Gemcitabine-containing regimens have also been used succes...
متن کاملWeekly docetaxel in the treatment of metastatic breast cancer
Breast cancer is the most frequent tumor among women worldwide and is the second cause of cancer-related mortality in the US. Metastatic breast cancer (MBC) accounts for less than 10% of newly diagnosed breast cancer patients and about 30% of early breast cancer patients will develop recurrent, advanced, or metastatic disease. It remains an incurable illness and the primary goal of its manageme...
متن کاملPhase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
BACKGROUND Triple-negative breast cancer is an aggressive disease with unmet clinical needs. In a phase III study of patients with metastatic triple-negative breast cancer, first-line gemcitabine/carboplatin resulted in a median progression-free survival of 4.6 months. nab-paclitaxel-based regimens (with gemcitabine or carboplatin±bevacizumab) also demonstrated efficacy and safety in first-line...
متن کاملAlbumin-Bound Paclitaxel in the Treatment of Metastatic Breast Cancer
The taxanes, paclitaxel and docetaxel, are an important class of antineoplastic agents with relevant clinical activity in both early and advanced breast cancer. Nanoparticle albumin-bound paclitaxel (Abraxane®) is a 130–nm particle cremophor-free formulation of paclitaxel. Exploiting endogenous albumin pathways and avoiding solvent-based toxicities, nab-paclitaxel allows higher intratumor conce...
متن کاملGemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
Gemcitabine has been evaluated in combination with paclitaxel, docetaxel, anthracyclines, vinorelbine, and cisplatin as first-line treatment and after prior chemotherapy in patients with metastatic breast cancer. Results with gemcitabine/taxane combinations have been especially encouraging, with these combinations providing promising outcomes with regard both to tumor response and tolerability....
متن کامل